Spyre Therapeutics, Inc.
86.93USD
-3.8600 (-4.25%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.83▼ | $-0.69 | 2 | 8 |
| Next quarter | $-0.87▼ | $-0.66 | 3 | 9 |
| Current year | $-2.88▼ | $-2.84 | 9 | 3 |
| Next year | $-3.52▼ | $-3.06 | 3 | 8 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.75 | $-0.36 | +0.39 (+51.8%) |
| 2026-03-31 | $-0.65 | $-0.74 | -0.09 (-13.1%) |
| 2025-12-31 | $-0.8 | $-0.74 | +0.06 (+7.2%) |
| 2025-09-30 | $-0.74 | $-0.15 | +0.59 (+79.7%) |
51 ratings from 16 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| BTIG | Reiterated | Buy | $121 | Sep 8, 2026 |
| Deutsche Bank | Maintained | Buy | $135 $127 | Aug 26, 2026 |
| Wedbush | Maintained | Outperform | $130 $123 | Aug 26, 2026 |
| BTIG | Maintained | Buy | $132 $121 | Aug 26, 2026 |
| BTIG | Maintained | Buy | $112 $132 | Aug 11, 2026 |
| Wells Fargo | Maintained | Overweight | $90 $115 | Aug 5, 2026 |
| Guggenheim | Maintained | Buy | $115 $130 | Aug 5, 2026 |
| Wedbush | Maintained | Outperform | $100 $130 | Aug 5, 2026 |
| Wolfe Research | Downgraded from Outperform | Peer Perform | — | Jul 28, 2026 |
| Mizuho | Maintained | Outperform | $84 $120 | Jul 13, 2026 |
| Deutsche Bank | Maintained | Buy | $115 $135 | Jun 23, 2026 |
| BTIG | Maintained | Buy | $98 $112 | Jun 15, 2026 |
| Deutsche Bank | Maintained | Buy | $102 $115 | Jun 4, 2026 |
| Citigroup | Maintained | Buy | $64 $97 | May 6, 2026 |
| Stifel | Maintained | Buy | $92 $107 | May 6, 2026 |
| Jones Trading | Maintained | Buy | $64 $95 | Apr 17, 2026 |
| Wells Fargo | Maintained | Overweight | $50 $90 | Apr 14, 2026 |
| Wedbush | Maintained | Outperform | $65 $80 | Apr 14, 2026 |
| Baird | Maintained | Outperform | $65 $90 | Apr 14, 2026 |
| Raymond James | Initiated | Strong Buy | $80 | Apr 14, 2026 |
| Deutsche Bank | Maintained | Buy | $55 $88 | Apr 14, 2026 |
| Leerink Partners | Maintained | Outperform | $49 $106 | Apr 13, 2026 |
| Jefferies | Maintained | Buy | $47 $85 | Apr 13, 2026 |
| BTIG | Maintained | Buy | $70 $98 | Apr 13, 2026 |
| BTIG | Reiterated | Buy | $70 | Mar 31, 2026 |
62 filings from 9 insiders · 14 buy / 22 sell over 6m
Officers and directors of SYRE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| King-Jones HeidyOfficer, See Remarks | ExerciseStock Option (Right to Buy) | 400 | — | — | Sep 2, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 400 | $90.00 | $36k | Sep 2, 2026 |
| King-Jones HeidyOfficer, See Remarks | Exercise | 400 | $14.50 | $6k | Sep 2, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 18.2k | $89.35 | $1.63M | Sep 2, 2026 |
| King-Jones HeidyOfficer, See Remarks | ExerciseStock Option (Right to Buy) | 28.0k | — | — | Sep 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 400 | $89.38 | $36k | Sep 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 6.2k | $88.17 | $547k | Sep 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 16.5k | $87.20 | $1.44M | Sep 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 4.8k | $86.40 | $419k | Sep 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Exercise | 28.0k | $14.50 | $406k | Sep 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | ExerciseStock Option (Right to Buy) | 7.5k | — | — | Sep 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 200 | $89.04 | $18k | Sep 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 2.0k | $88.03 | $177k | Sep 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 4.4k | $87.11 | $382k | Sep 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 900 | $86.25 | $78k | Sep 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Exercise | 7.5k | $14.50 | $109k | Sep 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 400 | $89.07 | $36k | Sep 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 3.7k | $88.06 | $326k | Sep 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 8.4k | $87.15 | $732k | Sep 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 2.5k | $86.36 | $216k | Sep 1, 2026 |
No analyst notes on SYRE yet.
Analyst Ratings
13 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 15 | 1 | 0 | 0 | Buy2.06 |
| 1 mo ago | 0 | 16 | 1 | 0 | 0 | Buy2.06 |
| 2 mo ago | 0 | 16 | 1 | 0 | 0 | Buy2.06 |
| 3 mo ago | 0 | 17 | 0 | 0 | 0 | Buy2.00 |